 BidaskClub cut shares of Eiger Biopharmaceuticals NASDAQ:EIGR from a sell rating to a strong sell rating in a research report released on Friday morning, BidAskClub reports. Other research analysts have also recently issued research reports about the stock. Wedbush reiterated a buy rating and issued a 34.00 target price on shares of Eiger Biopharmaceuticals in ... 